atepeq/tico19 huggingface dataset:
The RCGP RSC extracts pseudonymized data from a nationally representative sample of over 500 urban and nonurban GPs each week covering a population of over 4 million.
RCGP RSC kiggya obubaka obukwekeze okuva mu sampolo ekikiirira eggwanga lyonna okuva mu bantu b’omu bibuga n’abatali ba mu bibuga 500 mu GP buli wiiki okuva mu bantu abasukka mu bukadde 4.
Data from these practices are reported online in a weekly return, which includes monitoring weekly rates of influenza-like illness (ILI) and other communicable and respiratory diseases in England.
Obubaka obuva mu kukola okwo bulagibwa ku muyungiro gwa yintaneeti mu buli wiiki, omuli okulondoola emiwendo gy’obulwadde obwefaananyiriza yegu (influenza-like illness (ILI)) buli wiiki wamu n’endwadde endala ez’omuyungiro gw’okussa mu Bungereza.
We also produce an annual report.
Tukola ne alipoota eya buli mwaka.
The RCGP RSC data set includes all coded data and all prescribed items including vaccine exposure.
Obubaka bwa RCGP RSC bulimu obubaka obuliko ennamba wamu n’ebintu ebirala ebinnyonnyoddwa omuli n’eddagala erigema.
The RCGP RSC conducts virology surveillance each influenza season, with 100 GPs participating in the 2019-2020 season (Figure 1).
RCGP RSC kikola okunoonyereza ku buwuka buli mulundi yegu w’abeerera omungi, nga mulimu GPS 100 ezeetabamu mu kiseera ekya 2019-2020 (Ekifaananyi 1).
These virology sampling practices are also recruited to be nationally representative (Figure 1).
Okukuŋŋaanya sampolo z’okunoonyereza ku buwuka era kutwalibwa ng’okukiikirira eggwanga lyonna (Ekifaananyi 1).
GPs take nasopharyngeal swabs from persons showing acute respiratory illness within 7 days of the onset of symptoms.
GPs bayisa obuwero mu nnyindo ne mu mimiro (nasopharyngeal swabs) okuva ku bantu abalabikirako obubonero bw’okukosebwa ennyo mu kussa mu bbanga lya nnaku 7 okuva obubonero lwe butandise okubeeyolekerako.
Nasopharyngeal swabs are taken from children younger than 5 years showing symptoms of acute bronchitis or bronchiolitis.
Okuyisa obuwero mu nnyindo ne mu mimiro (nasopharyngeal swabs) kikolebwa ku baana abataweza myaka 5 egy’obukulu abalabikirako obubonero bw’olufuba (acute bronchitis) oba bronchiolitis.
Additionally, nasopharyngeal samples are taken from anyone 5 years and older showing acute onset of ILI and respiratory synctial virus.
Mu ngeri y’emu, sampolo eziggyibwa mu nnyindo ne mu mimiro (nasopharyngeal samples) ziggyibwa ku muntu yenna alina emyaka 5 n’okusingawo alabikirako obubonero bwa ILI obw’amaanyi wamu n’akawuka akayitibwa respiratory synctial virus.
Swabs are tested at the PHE Respiratory Virus Unit for influenza to monitor positivity rates and circulating strains, as well as for measuring vaccine effectiveness.
Obuwero bukebererwa mu kitongole kya PHE Respiratory Virus Unit okulaba oba mulimu yegu okulondoola emiwendo gy’abo abalina obulwadde n’ensaasaana wamu n’okupima enkola y’eddagala erigema.
The RCGP RSC successfully conducted a pilot collecting serological samples from adults and linking them to a patient’s medical records during the 2018-2019 influenza season.
RCGP RSC yakola bulungi okugezesa kw’okukuŋŋaanya sampolo z’omusaayi (serological samples) okuva mu bantu abakulu n’okuzikwanaganya n’ebiwandiiko by’abalwadde eby’ekisawo mu kiseera kya yegu ekya 2018-2019.
This pilot was in collaboration with the PHE Seroepidemiology Unit and added to the residual blood samples submitted to PHE by National Health Service (NHS) laboratories.
Okugezesa kuno kwakolerwa wamu n’ekitongole kya PHE Seroepidemiology Unit era kwayongera ku sampolo z’omusaayi ogwasigalawo ogwaweerezebwa ku PHE nga kikolebwa amagezeserezo ga National Health Service (NHS) laboratories.
Serology can provide important information about background population immunity, and sentinel networks can provide a mechanism for systematic data collection and linkage to medical records and health outcomes.
Okukebera omusaayi (Serology) kusobola okukuwa obubaka obw’omugaso obukwata ku byafaayo by’obusibage bw’abantu, ate obunyigirizi mu nkolagana (sentinel networks) busobola okuteekawo enkola y’okukuŋŋaanya obubaka n’okukwanya ebiwandiiko by’ekisawo n’ebivaamu.
The serology pilot has demonstrated the ability of the network to collect serology samples in adults.
Okugezesa kw’okukebera amazzi g’omu mubiri (serology) kulaze obusobozi bw’obuyungirizi mu kukuŋŋaanya sampolo mu bantu abakulu.
With the COVID-19 outbreak, PHE and RCGP RSC have adapted existing influenza surveillance to monitor the spread of COVID-19 in the community, and this protocol sets out the basis for that collaboration.
Olw’okubalukawo kwa nawookera wa COVID-19, PHE ne RCGP RSC bikozesezza okulondoola okuliwo ku yegu okulondoola ensaasaana ya COVID-19 mu bantu, era enkola eno y’eteekawo omusingi gw’okukolagana okwo.
The primary national strategy for COVID-19 infection is containment, with patients who are at high risk managed via the telephone help system NHS111 and the PHE health protection teams, but the RCGP RSC surveillance is entirely separate.
Akakodyo akasookerwako ak’eggwanga ku bulwadde bwa COVID-19 kwe kumutangira obutasaasaana, mu balwadde abali mu bulabe obw’amaanyi abakolebwako n’okubakubira essimu mu nkola ya NHS111 ey’okubayamba wamu n’abayambi b’ebyobulamu aba PHE, naye okulondoola kwa RCGP RSC kwo kwa njawulo ddala.
The RCGP RSC, by extending its established work, will provide virological and serological surveillance to monitor the temporal and geographical distribution of COVID-19 infection in the community, and assess the effectiveness of the containment strategy.
RCGP RSC, mu kigaziya emirimu gyakyo gye kikola, kijja kukola ku kulondoola eby’omunda n’eby’omu bitundu ebirala ebikwata ku bulwadde bwa COVID-19 wamu n’okwekaliriza enkola y’obukodyo obukozesebwa okulwanyisa obulwadde buno.
We would not be working in isolation on this research.
Tetuyinza kuba nga tukola ffekka ku kunoonyereza kuno.
We will share the protocol with UK colleagues and the I-MOVE consortium who have recently obtained EU Horizon 2020 funding from the stream “Advancing knowledge for the clinical and public health response to the novel coronavirus epidemic”.
Tujja kugabana enkola ne bannaffe ab’omu UK era enzikaanya ya I-MOVE abaafuna emabegako awo ssente z’okunoonyereza eza EU Horizon 2020 okuva mu “Advancing knowledge for the clinical and public health response to the novel coronavirus epidemic”.
It is anticipated that great efficiencies in project management will result through this collaboration than that obtained from countries acting alone.
Kiteeberezebwa nti okukola obulungi okusinga mu nkwata ya pulojeti kujja kuva mu nkolagana eno okusinga bwe kiri mu mawanga agakola gokka.
The aim of this study is to identify whether there is undetected community transmission of COVID-19, estimate population susceptibility, and monitor the temporal and geographical distribution of COVID-19 infection in the community.
Ekiruubirira ky’okunoonyereza kuno kwe kuzuula oba nga waliwo okusaasaanya kwa COVID-19 mu bantu okutakengeddwa, okuteebereza abantu abali mu buzibu, n’okulondoola abantu ab’omunda n’ab’omu kitundu ekinene omusaasaanidde COVID-19 mu kitundu.
The objectives of this study are as follows:
Ebigendererwa by’okunoonyereza kuno bye bino:
To monitor the burden of suspected COVID-19 activity in the community through primary care surveillance and clinical coding of possible COVID-19 cases referred into the containment pathway
Okusoola okulondoola okuteeberezebwa kwa COVID-19 mu bitundu nga tuyitira mu kulondoola obujjanjabi obusookerwako n’okulamba okw’ekisawo okw’abayinza okuba ne COVID-19 abaweerezebwa mu bifo gye bakuumirwa
To provide virological evidence on the presence and extent of undetected community transmission of COVID-19 and monitor positivity rates among individuals presenting ILI or acute respiratory tract infections to primary care
Okuleeta obubaka obukwata ku kunoonyereza ku buwuka ku kubeerawo wamu n’obusaasaane bw’obulwadde bwa COVID-19 wamu n’okulondoola abantu abalina obulwadde mu bantu kinnoomu abeeyolekerako obuzibu bwa ILI oba obuzibu obw’amaanyi obw’omuyungiro gw’okussa mu bujjanjabi obusookerwako
To estimate baseline susceptibility to COVID-19 in the community and estimate both symptomatic and asymptomatic exposure rates in the population through seroprevalence monitoring
Okuteebereza ebisookerwako mu kukosebwa COVID-19 mu kitundu era n’okuteebereza abeeyolekerako obubonero n’abeeyolekerako obubonero mu bantu nga tuyitira mu kulondoola abantu abalina obulwadde (seroprevalence)
To pilot implementation of a scheme for collection of convalescent sera with antibody profiles among recovered cases of COVID-19 discharged to the community
Okugezesa enkozesa y’enkola y’okukuŋŋaanya sampolo z’abalwadde abagenda bawona nga tukozesa antibody profiles mu balwadde ba COVID-19 abawonye ne basiibulwa ne baddayo mu bitundu byabwe
We intend to capture the following.
Tusuubira okukuŋŋaanya bino wammanga.
Clinical workload related to reports of COVID-19 using the codes created to flag cases, those being assessed and where the infection is located are excluded (Figures 2-​-44)
Emirimu gy’ekisawo egyekwanya ku alipoota za COVID-19 nga tukozesa koodi eziteekebwa ku balwadde, abo abeekalirizibwa ate n’ekifo obulwadde we buli tebibalibwa (Ebifaananyi 2-​-44)
Foreign countries visited in the last 28 days
Amawanga g’ebweru agakyaliddwa mu nnaku 28 eziyise
Existing codes that may have utility (Tables 1-​-3).3).
Koodi eziriwo eziyinza okubeera n’omugaso (Emyeso 1-​-3).3).
Many GPs and primary care teams may not realize that important relevant data can be coded.
Abasawo aba Bulijjo (GPs) bangi n’abakola ku bujjanjabi obusookerwako bayinza obutakirengera nti obubaka obw’omugaso obwetaagisa bwetaagisa okuteekebwako ennamba.
There is also the potential during any pandemic to monitor the effectiveness of any transmission control measures.
Waliwo n’obusobozi mu kiseera kya nawookera okulondoola obulungi bw’enkola z’okutangira okusaasaana kw’obulwadde.
Reliable coding of letters and test results that will show an infection has become either confirmed or excluded
Okuteeka koodi ku bubaka okwesigika ne ku bivudde mu kukebera okunaalaga obulwadde kufuuse okukakasibwa oba okutabalibwa
The methods will follow the approach used in the current influenza surveillance system and recent serology study, and includes five components: (1) primary care clinical surveillance; (2) virological surveillance; (3) population serological surveillance; (4) convalescent sera in cases; and (5) data curation.
Obukodyo bujja kugoberera enkola egobererwa mu kulondoola yegu mu kiseera kino n’okunoonyereza ku musaayi okwakolebwa emabega era kulimu ebintu bitaanu: (1) Okulondoola obujjanjabi obusookerwako; (2) okulondoola obuwuka (virological surveillance); (3) okulondoola okunoonyereza ku musaayi mu bantu; (4) okunooyereza ku balwadde abagenda bawona; ne (5) okukola ku bubaka obukuŋŋaanyiziddwa.
The NHS uses the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) system of coding, which is normally only updated twice annually.
NHS kikozesa enkola ya Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) ey’okuteekako koodi, ng’enkola eno ezzibwa obuggya emirundi ebiri gyokka buli mwaka.
There was added complexity as some computerized medical record (CMR) suppliers use the Read coding systems (Read clinical terms version 3 – CTv3), which is no longer updated.
Waaliwo n’obuzibu obulala obweyongerako nga ebiwandiiko by’eddwaliro ebimu eby’oku kompyuta (CMR) bikozesa enkola ya Read coding systems (Read clinical terms version 3 – CTv3), ate nga yo tekyazzibwa buggya.
Additionally, there were no clinical codes to record COVID-19 in early February 2020.
Mu ngeri y’emu, tewaaliwo koodi za kisawo okuwandiika COVID-19 mu mwezi Gwokubiri 2020 nga gutandika.
Therefore, the two main GP system suppliers added the five terms shown in Table 4 as system-wide local codes.
Awo nno, Enkola enkulu ebbiri eza ba GP abaweereza baayongeramu ebimiimo bitaanu ebiragiddwa mu Mweso 4 nga koodi z’omu muyungiro ezikozesebwa mu kitundu.
A UK emergency release of SNOMED CT concepts for COVID-19 was also subsequently made available across all CMR systems (Table 4).
Okufulumya okwakolebwa mu UK okwa SNOMED CT concepts for COVID-19 kwateekebwa mu miyungiro gya CMR (Omweso 4).
The intention is that these will eventually be mapped to the new SNOMED CT concepts as they become available, allowing recording of relevant data (Multimedia Appendix 1).
Ekigendererwa kye kino nti oluvannyuma lwa byonna bino bijja kulambiwa ku bitegeero bya SNOMED CT nga bwe binaaba bizuulibwa, ng’obubaka obwetaagisa buwandiikibwa (Ekikookero kya Multimedia 1).
The key requirements for this release were the ability to code (Table 4) a case of COVID-19, exposure to risk of infection (travel to an area where there may be a higher risk), contact with anyone infected with COVID-19, a report that a person had been tested for COVID-19, and that the disease had been excluded (likely a negative test).
Ekyetaagisa ekikulu eky’olufulumya luno bwe busobozi bw’okuteeka ennamba (Omweso 4) ku mulwadde wa COVID-19, okubeera mu bulabe bw’okukwatibwa obulwadde (okugenda mu kifo ewayinza okubeera obulabe obw’amaanyi), okukwatagana n’omuntu yenna alina COVID-19, alipoota etegeeza nti omuntu yali akebeddwa COVID-19, era nti obulwadde bwali tebulabiddwa (nga kirabika talina bulwadde).
In addition, practices are now able to code any foreign travel undertaken, including the ability to record visits to multiple countries (implemented February 8, 2020).
Okwongereza ku ekyo, ebikolebwa kati bisobola okulamba okutambula kwonna omuntu kw’agenzeeko ebweru, omwo nga mwe muli n’obusobozi bw’okuwandiika okukyala mu mawanga ag’enjawulo (kyatandika nga 8 Ogwokubiri 2020).
Figures 2-​-44 show the EMIS web implementation.
Ebifaananyi 2-​-44 biraga enkola ya EMIS ey’oku mutimbagano.
Currently, virology samples for influenza surveillance are accompanied by a standard request form.
Mu kiseera kino, sampolo z’okunoonyereza ku buwuka (virology samples) ku kulondoola yegu ziteekebwako foomu eya bulijjo esaba.
For COVID-19, we will create a new request form that will record:
Ku lwa COVID-19, tujja kukola foomu empya ey’okusibirako ewandiikibwamu:
Date of onset of symptoms
Ennaku z’omwezi obubonero lwe butandise
Diagnosis of any of the following:
Okukebera ekimu ku bino wammanga:
Acute bronchitis/bronchiolitis in those younger than five years
Olufuba olw’amaanyi/bronchiolitis mu abo abataweza myaka etaanu
Lower respiratory tract infection (LRTI)
Obuvune mu kitundu ky’omussizo ekya wansi (LRTI)
History of fever (Y/N); measured (Y/N); if yes, level
Ebyafaayo by’omusujja (Yee/Nedda); apimiddwa (Yee/Nedda); bwe kiba yee, eddaala
Shortness of breath (Y/N), if measured: oxygen saturation and respiratory rate
Okubaka omukka (Yee/Nedda), bw’aba apimiddwa: omukka gw’alina mu mubiri n’embiro kw’assiza
Recent travel (Y/N); if yes, countries visited in last 14 days
Okutambula okw’emabegako (Yee/Nedda); bwe kiba yee, amawanga ge yakyalamu mu nnaku 14 eziyise
Contact with a named person with confirmed COVID-19 (Y/N) with a free text comment about the level of certainty
Okukwatagana n’omuntu ayogeddwako alina COVID-19 (Yee/Nedda) nga waliwo ebigambo ebiraga okwekakasa ku bulwadde bw’omuntu oyo
These codes will be grouped ontologically into “definite”, “probable”, “possible”, and “not a case” using our standard approach to grouping codes (Table 5), which has been used previously across disease areas.
Koodi ezo zijja kubinjawazibwa okusinziira nga bwe zajjja mu bibinja nga “kikakasika”, “kirabika”, “kisoboka”, ne “si mulwadde” nga tukozesa enkola yaffe ey’okubinjawaza koodi (Omweso 5), eyakozesebwako emabegako mu bifo by’endwadde.
The RCGP RSC definition for ILI is shown in Multimedia Appendix 2.
Enyinyonnyola ya RCGP RSC eya ILI eragibwa mu Nkookero ya Multimedia 2.
Public Presentation of Data Using an Observatory and Dashboards
Okulaga obubaka mu lwatu omuli Okukozesa Ekyekalirizo (Observatory) ne Dashboards
We will develop an observatory to present data nationally and a dashboard for feedback to practices about their data quality and collection of virology and serology samples.
Tujja kukolawo ekyekalirizo okulagiramu obubaka mu ggwanga lyonna ate ne dashboard tufuniremu ebiva mu bantu ku bikwata ku bikolebwa ku mutindo gw’obubaka n’enkuŋŋaanya y’obubaka obw’okunoonyereza ku buwuka wamu n’okunoonyereza ku musaayi.
This is based on coding described in Table 4.
Kino kyesigamiziddwa ku kuteekako ennamba okulagiddwa mu Mweso 4.
Definite case will be presented on our dashboard as “cases” of COVID-19.
Omulwadde akakasiddwa ajja kulagibwa ku dashboard yaffe nga “abalwadde” ba COVID-19.
Possible cases will be presented as “Under investigation” (investigating).
Abalabika okuba abalwadde bajja kulagibwa nga “Abakyanoonyerezebwako” (okunoonyereza).
“Not a case” will be presented as “Excluded”.
“Si mulwadde” ajja kulagibwa nga “Tateereddwamu”.
Online data has been established within the initial few weeks in the COVID-19 Observatory (Figure 5), indicating the overall number of patients and rate per 10,000 patients of cases confirmed or under investigation, as well as where the virus is excluded.
Obubaka obw’oku mutimbagano bukakasiddwa mu wiiki entono ezaasooka mu Kyekalirizo kya COVID-19 (Ekifaananyi 5), ekiraga omuwendo gw’abalwadde bonna n’ekigero ky’abalwadde ku buli balwadde 10,000 abakakasiddwa oba abakyanoonyerezebwako ate ne mu mbeera akawuka we kataafiibwako.
We have the option to move to twice weekly surveillance reports with a scope to change this to daily reporting.
Tulinawo omukisa gw’okutandika okukolera ku mirundi ebiri mu wiiki nga tukola alipoota z’okulondoola nga tulina n’ebbanga ery’okukyusa ne tudda ku kuwa alipoota buli lunaku.
We will continue virology sampling from our sentinel practices, rather than discontinuing as seasonal influenza declines.
Tujja kweyongera okukuŋŋaanya sampolo z’okunoonyereza ku buwuka okuva mu bye tukola okunoonyereza ku bitundu omuli obulwadde, mu kifo ky’okubisazaamu ng’ekiseera kya yegu kikendedde.
Additionally, we will recruit more surveillance practices.
Mu ngeri y’emu, tujja kuleeta enkola z’okulondoola endala.
The RCGP RSC virology practices will aim to undertake 200-300 nasopharyngeal swabs per week across the RCGP RSC sentinel network, collecting specimens across all age bands.
RCGP RSC by’ekola ku kunoonyereza ku buwuka bijja kuluubirira okuggya sampolo z’omu nnyindo ne mu kamwa 200-300 buli wiiki mu bitundu bya RCGP RSC byonna bye bakoleramu okulaba ebifo omuli obulwadde, nga bakuŋŋaanya sampolo mu bantu ab’emyaka gyonna.
In addition to the inclusion criteria for influenza virology surveillance (ILI, acute bronchitis/bronchiolitis), participating practices will take nasopharyngeal swab samples from any people showing acute symptoms of LRTI if the onset of symptoms is within 7 days.
Okwongereza ku ky’akakwakkulizo k’okwongeramu okulondoola obuwuka ku yegu (ILI, acute bronchitis/bronchiolitis), abakola bajja kukuŋŋaanya sampolo z’omu nnyindo ne mu kamwa okuva ku bantu ab’engeri yonna abeeyolekerako obubonero bwa LRTI kasita kiba nti obubonero obusoose bulabikidde mu nnaku 7 ezisooka.
RCGP RSC research officers and practice liaison staff will manage practices to achieve a total national sample of 200-300 swabs per week.
Abanoonyereza ba RCGP RSC n’abakola ku nsonga z’abantu bajja kukola ku bikolebwa okufuna sampolo za swab 200-300 mu ggwanga lyonna buli wiiki.
This could be increased if PHE modelers require more samples.
Ziyinza okwongezebwa singa abakola ku PHE beetaaga sampolo endala.
Samples from each practice would be spread across the following age groups: &lt; 5 years, 5-17 years, 18-64 years, and 65 years and older
Sampolo okuva mu buli ekikolebwa zijja kuggyibwa mu bantu ab’emyaka egy’enjawulo: abataweza myaka 5, myaka 5-17, myaka 18-64, n’emyaka 65 years n’okusingawo
Samples (swabs or serum) collected will be sent via prepaid envelopes addressed to the appropriate PHE laboratory for analysis.
Sampolo (swabs oba serum) ezinaakuŋŋaanyizibwa zijja kuweerezebwa mu mabaasa aganaaba gamaze okusasulirwa mu magezeserezo ga PHE agasaanidde zeekalirizibwe.
All samples collected will be tested for the presence of influenza and COVID-19.
Sampolo zonna ezikuŋŋaanyizibwa zijja kukeberebwa okulaba oba nga mulimu yegu ne COVID-19.
Additionally, PHE will retrospectively test any influenza virology samples collected between early and mid-February 2020 for COVID-19.
Mu ngeri y’emu, PHE kijja kuddayo kikebere sampolo z’obuwuka bwa yegu ezaakuŋŋaanyizibwa mu Gwokubiri wakati, 2020 okulaba oba nga mulimu COVID-19.
Practices will still follow the PHE protocol for COVID-19 with respect to people at risk of infection who should be signposted down the containment pathway, rather than physically attend their practice.
Ebikolebwa PHE bijja kweyongera okugoberera enseetuka ya COVID-19 nga bafaayo ku bantu abali mu buzibu bw’okukwatibwa obulwadde abalina okufiibwako mu kaweefube w’okutangira ekirwadde mu kifo ky’okubatuukako obutereevu.
Direct testing of those who attend surgery remains permitted, but we have also rolled out self-swabbing at home.
Okukebera obutereevu okw’abo abalongoosebwa kukkirizibwa naye nga kati tutaddewo n’entegeka y’omuntu okwekolera swab ewaka.
Summary of processes are detailed in Multimedia Appendix 3.
Ekifunze ky’enkwajja kinnyonnyoddwa mu Kikookero kya Multimedia 3.
Everyone with an ILI or a respiratory illness who contacts a GP (eg, phones for an appointment) should be asked specifically about recent travel to China and other countries flagged in current PHE advice, or if they have had contact with other people with COVID-19.
Buli muntu yenna alina ILI oba obulwadde bw’okussa era ng’atuukiridde GP (okugeza, n’akuba essimu okukola akalagaane) alina okubuuzibwa oba ku ntambula ze yakola emabegako e China ne mu mawanga amalala agalambibwa mu kimanyiso kya PHE, oba bw’aba ng’abadde akwataganyeeko n’abantu abalala abalina COVID-19.
If these screening enquiries are positive, the patient would be advised to not come to the practice but instead to follow the PHE flow sheet.
Okukebera kuno bwe kulaga nti balina obulwadde, omulwadde aweebwa amagezi aleme kujja kumujjanjaba naye agoberere ebiragibwa PHE.
This can be by a reception or clinician staff, depending on individual practice protocol.
Kino kisobola okukolebwa omuntu atuukirwako ku kifo oba omusawo, okusinziira ku nseetuka ya buli omu nga bw’eri.
These calls should be coded into the GP CMR system and can be reported as part of the RCGP RSC weekly return.
Amasimu gano agakubibwa galina okuweebwa ennamba mu muyungiro gwa GP CMR era galina okulagibwa ng’ekitundu ku bikolebwa RCGP RSC buli wiiki.
We have developed training material to support this coding (Multimedia Appendix 4).
Tuteeseteese ebiwandiiko ebitendekerwako okuwagira enkola y’okuteekako ennamba (Ekikookero kya Multimedia 4).
These include prompt cards for:
Muno muzingiramu kaadi ez’amangu eza:
Practice reception or triage staff: for coding of any patients calling the practice with symptoms of acute respiratory infection with a history of travel to important areas based on PHE advice
Abakola ku kifo ewatuukirwa oba abategeka abalwadde: okuwa ennamba omulwadde yenna akuba essimu okufuna obujjanjabi ng’alina obubonero obw’amaanyi mu kussa ate nga yatambulako mu bifo ebikulu okusinziira ku kimanyiso kya PHE
Administrative staff or clinicians who code: to encourage consistent coding of results for any suspected cases, including coding of negative results for exclusion
Abakola ku nsonga z’obukulembeze oba abasawo abateekako ennamba: okuwagira okuteekako ennamba entakera ku biva ku mulwadde yenna ateeberezebwa, omwo nga mwe muli n’okuwa ennamba ebivudde mu kukebera eby’atalina bulwadde byawulwe
Practices participating in virology surveillance will opportunistically collect blood samples from patients coming into the practice for a routine blood test.
Abakola ku kulondoola okunoonyereza ku buwuka bajja kubeera n’omukisa gw’okukuŋŋaanya sampolo z’omusaayi okuva ku balwadde abakeberwa omusaayi oluvannyuma lw’akaseera.
Patients who attend their practice for a routine blood test will be asked to provide an additional sample for serology.
Abalwadde abagenda okubajjanjaba olw’okubaggyako omusaayi ogwa bulijjo bajja kusabibwa okuwaayo sampolo y’omusaayi omulala olw’okukola okunoonyereza kw’omusaayi.
We have conducted initial searches within the RCGP RSC database to look at the number of full blood count (FBC) results and overall rates in adults and children (Figures 6-​-9).9).
Tukoze okunoonya okusooka mu kkuŋŋaanyizo lya RCGP RSC okulaba omuwendo gw’ebiva kukebera omusaayi okujjuvu (FBC) wamu n’emiwendo egy’awamu mu bantu abakulu n’abaana (Ekifaananyi 6-​-9).9).
An FBC is one of the most common tests performed, and we hope this will give an approximate indication of overall numbers of blood tests performed.
FBC y’emu ku kukebera okukolebwa, era tusuubira nti kino kijja kuwa okuteebereza ku miwendo egy’awamu egy’omusaayi ogukeberwa.
The sampling rate, per 100,000 patients was highest for children 15-17 years of age and 60 year or older in adults, with the lowest rates in children 0-4 years of age and 18-29 years of age in adults (Figures 6-​-99).
Omuwendo ogukebererwako, ku buli balwadde 100,000 gwali waggulu mu baana ab’emyaka 15-17 egy’obukulu n’ab’emyaka 60 oba okusingawo mu bakulu, era ng’omuwendo omutono gwali mu baana ab’emyaka 0-4 egy’boukulu ne 18-29 egy’oubkulu mu bakulu (Ekifaananyi 6-​-99).
We will provide 1000 serology baseline samples across all ages that reflect the varying rates of attendance by age.
Tujja kuwaayo sampolo z’okunoonyereza ku musaayi ezisookerwako 1000 mu bantu ab’emyaka gyonna abalaga enkyukakyuka y’emiwendo gy’abo abakolebwako okusinziira ku myaka.
Additionally, we will test if we can obtain these all from virology practices to enhance the yield.
Okwongereza ku ekyo, tujja kugezesa oba nga tusobola okubifuna byonna okuva mu bujjanjabi bw’okunoonyereza ku musaayi olw’okwongera okunyweza ebizuulibwa.
A good geographical spread is important, so PHE can advise on areas where serology will most usefully be collected.
kikulu nnyo okukolera mu bifo eby’enjawulo, awo nno PHE nakyo kijja kuwa amagezi ku bifo ebigasa okukoleramu okunoonyereza ku musaayi.
This will be followed by 800 samples monthly.
Kino kijja kugobererwa sampolo 800 buli mwezi.
The sample will be stratified with 200 specimens for prepandemic survey (100 for monthly) in the following age groups: &lt; 5 years, 5-17 years, 18-64 years, and 65 years or older.
Sampolo ejja kubinjawazibwa mu butu (specimen) 200 mu kunoonyereza nga nawookera tannabaawo (100 buli mwezi) mu bibinja by’emyaka bino: emyaka egitawera 5, emyaka 5-17 , emyaka 18-64 , n’emyaka 65 n’okusingawo.
The younger patients, in many practices younger than 14 years, and in nearly all for children younger than 8 years will require pediatric serology surveillance.
Abalwadde ab’emyaka emimpi, mu kunoonyereza okusinga nga tebaweza myaka 14, ate ne mu kunoonyereza kumpi kwonna ku baana abataweza myaka 8 bajja kwetaaga okulondoola kw’okunoonyereza ku musaayi mu baana abato.
We will develop a new request form for practices to capture recent travel and exposure to COVID-19.
Tujja kukola foomu y’okusaba empya ey’obujjanjabi okufunirako ebikwata ku kutambula okwakolebwa emabegako n’okukwatagana ne COVID-19.
We will pilot a scheme for collecting convalescent serology from people with confirmed cases and who have had an acute virology sample at the time of their infection.
Tujja kukola okugeza kw’okukuŋŋaanya sampolo z’abalwadde abagenda bawona okunoonyereza ku musaayi gwabwe okuva mu bantu abaakakasibwa nti balwadde ate nga balina sampolo y’obuwuka obw’amaanyi mu kiseera obulwadde we bwabakwatira.
This is to identify a carrier state in patients who have recovered from the virus but may continue shedding the virus.
Kino kijja kuyambako mu kumanya embeera y’abalwadde abalina akawuka abawonye akawuka naye nga bayinza okweyongera okubeera n’akawuka.
If there are a small number of cases, this may assist in developing a test kit for patients to take to their own GP and explore its acceptability to patients.
Bwe kiba nga waliwo abalwadde batono, kino kiyinza okuyamba mu kukulaakulanya ekiyamba mu kukebera mu balwadde okutwala eri omusawo waabwe era ne bekkaanya engeri abalwadde baabwe gye bakirabamu.
If there are a large number of COVID-19 cases nationally, convalescent samples could be collected from RCGP RSC practices where there are confirmed cases, with the ability to link to the full medical record.
Bwe waba nga waliwo ennamba y’abalwadde ba COVID-19 nnene mu ggwanga lyonna, sampolo z’abalwadde abagenda bawona okuva mu bifo bya RCGP RSC bye baakakasibwa nti balwadde, n’obusobozi bw’okubikwataganaya n’ebiwandiiko by’ekisawo.
This process may include checking pseudonymized NHS numbers for positive individuals at RCGP RSC practices, checking current PHE guidance regarding considerations of infectiousness for confirmed cases, and offering the patient an appointment following the previously mentioned process.
Omutendera guno guyinza okubaamu okukebera ennamba za NHS enkwekeze ez’abantu abalina obulwadde mu bifo bya RCGP RSC, okukebera okuluŋŋamya kwa PHE okuliwo okukwata ku kufaayo ku kusiiga obulwadde ku balwadde abakakasiddwa, n’okulaga omulwadde lw’anajja ku ddwaliro nga bagoberera enkwajja eyayogerwako emabega.
This needs to be carefully coordinated nationally across the network and may require PHE to ensure individuals are not contacted by multiple agencies.
Kino kirina okukolebwako n’obwegendereza mu ggwanga lyonna mu ntabiro yonna era kiyinza okwetaagisa PHE okukakasa nti abantu tebatuukirirwa bitongole bya njawulo bingi.
RCGP RSC could provide a useful structure to channel the initial contact once PHE has made a request.
RCGP RSC kiyinza okulaga enkola ey’omugaso ey’okuweereza omuntu eyasooka okukwataganibwa naye kasita PHE ekola okusaba.
The RCGP RSC practices participating in the annual influenza virology surveillance have started sampling from patients showing symptoms of a LRTI.
Ebikolebwa RCGP RSC mu kunoonyereza ku kulondoola obuwuka bwa yegu okwa buli mwaka batandise okukuŋŋaanya sampolo okuva mu balwadde abeeyolekerako obubonero bwa LRTI.
All samples received are being tested for influenza and COVID-19.
Sampolo zonna ezaafunibwa zikeberebwa okulaba oba nga mulimu yegu ne COVID-19.
The RCGP RSC will explore ways to collect convalescent samples from any patients tested positive for COVID-19 through the extension of the virological surveillance.
RCGP RSC kijja kwekaliriza engeri y’okukuŋŋaanya sampolo z’abalwadde abagenda bawona okuva mu mulwadde yenna eyakeberebwa ng’alina COVID-19 nga kiyitira mu kwongezaayo okulondoola ku kunoonyereza ku buwuka.
From the start, we will be carefully curating data to ensure that it can be used for future studies.
Okuva olubereberye, tujja kwegendereza mu kwekaliriza obubaka tukakase nti busobola okukozesebwa mu kunoonyereza okujja mu maaso.
Our clinical data will be linked to virology.
Obubaka bwaffe obw’ekisawo bujja kukwanyizibwa n’obwo obw’okunoonyereza ku musaayi.
We will curate our data using the Findable, Accessible, Interoperable, Reusable principles.
Tujja kwekaliriza obubaka bwaffe nga tukozesa emisingi gya Findable, Accessible, Interoperable, Reusable.
To facilitate this our data set is listed with Health Data Research UK and the European Health Data Evidence Network.
Kino okukisobozesa obubaka bwaffe butegekeddwa wamu n’obwa Health Data Research UK ne European Health Data Evidence Network.
The statistical methodology is in support of a policy approach to widespread disease outbreak, where so-called nonpharmaceutical interventions (NPIs) are used to respond to an emerging pandemic to produce disease suppression.
Akakodyo k’ebibalo kawagira enkola y’okukwatamu nawookeera w’endwadde abunye wonna, omuli okukozesa enkola ezitaliimu ddagala (NPIs) okwaŋŋanga ekirwadde ekibaluseewo okufuna amagezi agalwanyisa ekirwadde.
This policy aims to reduce contact rates in the population and thereby reduce transmission of the virus.
Enkola eno eruubirira okukendeeza ku muwendo gw’okukwatagana mu bantu era mu ngeri eyo okusaasaanya akawuka ne kukendeera.
To implement this the UK government has recently articulated the desire to implement population self-isolation measures.
Okussa kino mu nkola, gavumenti ya UK emabegako awo yalaga obwetaavu bw’okussa mu nkola enkola y’abantu okweggya mu bannaabwe.
By targeting the reproduction number (R) (the average number of secondary cases each case generates) and aiming to reduce the R to below 1, the policy seeks to reduce case numbers to low levels or (as seen in previous outbreaks with severe acute respiratory syndrome and Ebola) to eliminate human-to-human transmission.
Nga tutunuulira ennamba y’okuzaalukana (R) (omuwendo omukkati ogw’abalwadde abasiigibwa buli mulwadde gw’aleeta) ate n’okuluubirira okukendeeza omuwendo (R) gubeere wansi wa 1, enkola eruubirira okukendeeza omuwendo gw’abalwadde gukke wansi oba (nga bwe kyalabibwa mu bulwadde obwabalukawo emabegako omwali obuzibu obw’amaanyi mu muyungiro gw’okussa ne Ebola) okumalawo okusaasaanya kw’obulwadde okw’okuva ku muntu omu okudda ku mulala.
As the experience from the 2009 H1N1 pandemic has shown, NPIs can be a crucial component of pandemic mitigation.
Ng’obumanyirivu ku nawookeera wa 2009 H1N1 bwe bulaze, NPIs kiyinza okubeera ekirungi eky’amaanyi mu kutangira nawookeera.
Key to the focus of our study will be the estimation of peak cases in the population and continual monitoring by data collection and modelling the potential growth and emergence of subsequent peaks in new cases as social distancing measures are relaxed.
Ekintu ekikulu mu kuweefube w’okunoonyereza kwaffe kijja kuba okuteebereza abalwadde ennyo mu bantu wamu n’okulondoola entakera nga tutunuulira enkuŋŋaanya y’obubaka n’enkolako yaabwo mu kulengera okweyongera kw’obulwadde n’okulaba oba nga bweyongera mu balwadde abapya amateeka g’obuteerinaana bwe ganaagenda nga gawewulwa.
There has already been publication of important disease epidemiological measures concerning the outbreak of COVID-19 in mainland China.
Waliwo okunoonyereza okumaze okufulumizibwa ku kukwata ku bulwadde n’ebikolebwa ku kubalukawo kwa COVID-19 mu ggwanga lya China.
A further fundamental measure in pandemic dynamics is the length of time from infection to when a person is infectious to others and the mean duration of infectiousness.
Ekintu ekirala ekikulu ekikolebwa mu kwaŋŋanga nawookeera bwe buwanvu bw’ebbanga okuva omuntu lw’abufunye ne w’atandikidde okubusiiga abalala wamu n’ebbanga ly’amala ng’abusiiga.
These factors, if estimated accurately, will give good predictions for the likely length of the pandemic, the final number of infected cases.
Ensonga zino bwe ziteeberezebwa obulungi zijja kuwa okuteebereza okulungi ku bbanga nawookeera ono ly’anaamala, omuwendo ogusembayo ogw’abalwadde.
We intend to apply approximate Bayesian inference (ABC) to (possibly spatially heterogeneous) Susceptible-Exposed- Infectious-Removed (SEIR) stochastic epidemic models.
Tusuubira okukozesa enkola za approximate Bayesian inference (ABC) to (possibly spatially heterogeneous) Susceptible-Exposed- Infectious-Removed (SEIR) stochastic epidemic models.
Such techniques are highly parallelizable and have been successfully applied to many fields including disease transmission modelling.
Obukodyo obw’engeri eyo bwawulibwa nnyo mu nneekaliriza era bukozeseddwa bulungi mu bisaawe bingi omwo nga mwe muli n’okuteebereza ensaasaana y’obulwadde.
They are particularly suited to situations where likelihood functions are absent and where more traditional approaches such as Markov chain Monte Carlo are impractical.
Bukozesebwa mu ngeri emu mu mbeera enteebereza ey’omugaso w’etabeererawo ate ne mu mbeera enkola eza bulijjo gamba nga Markov chain Monte Carlo nga tezisobola kukola.
Such an approach has been demonstrated to work effectively on the ASPREN surveillance data, a network of sentinel GPs and nurse practitioners who report deidentified information on ILIs and other conditions, where issues such as missing data and the need to model the observation process itself has been successfully addressed.
Enkola ey’engeri eyo eraze nti ekola bulungi ku kulondoola kw’obubaka bwa ASPREN, enkolagana ya GPs ey’ekiraga okubaawo kw’obulwadde n’abajjanjabi abategeeza obubaka obukwekeze ku ILIs n’embeera endala, awali ensonga gamba nga obubaka obutaliiwo n’obwetaavu bw’okukola ku nkwajja y’okwekaliriza yennyini ekoleddwako bulungi.
Furthermore, peaks in new cases have been estimated by distributional methods.
Ekirala, okutumbuka mu balwadde abapya kubadde kuteeberezebwa na nbukodyo bwa busaasaane.
Estimates of the parameters of the SEIR model are tractable on large data sets because of parallelizability, and these methods have been implemented in several R libraries; we intend to use the libraries ABSEIR (deposited on GitHub: https://tinyurl.com/vqu35cj) and abctools (https://tinyurl.com/tfjavz4) to estimate epidemic measures on a weekly basis.
Okuteebereza kw’obukodyo bwa SEIR model tekukola ku bubaka bungi olw’okuba nti busobola okwawulibwa era obukodyo buno bukozeseddwa mu magezeserezo mangi aga R libraries; tusuubira okukozesa libraries ABSEIR (ng’esangibwa ku GitHub: https://tinyurl.com/vqu35cj) ne abctools (https://tinyurl.com/tfjavz4) okuteebereza empima ya nawookeera buli wiiki.
Since we are fitting an SIR-epidemic model in the ABC routine, we anticipate that our results will be robust against weekly case data containing relatively small counts.
Olw’okuba nga tugyisa enkola ya SIR-epidemic model mu nkola ya ABC, tusuubira nti ebinaazuulibwa bijja kuba binnyonnyola bulungi obubaka bw’abalwadde obwa buli wiiki omuli emiwendo emitonoko.
For example, see for the ABC methodology applied to the Tristan da Cunha common cold data from 1967, where counts of I (number of infectious cases) and R (number of recovered cases) are in the tens at most.
Okugeza, laba enseetuka ya ABC eyateekebwa ku bubaka bwa ssennyiga wa Tristan da Cunha common cold mu 1967, omwali omuwendo gwa I (omuwendo ogw’abalwadde abasiiga) ne R (omuwendo gw’abalwadde abaawona) gwali awo okusinga ennyo mu makumi.
Finally, in addition to the above methodology we will employ the Kaplan-Meier method with two outcomes (death and recovery) to estimate the case fatality ratio.
Ekisembayo, ng’oggyeeko akakodyo akoogeddwako waggulu tujja kukozesa enkola ya Kaplan-Meier omuli ebivaamu eby’emirundi ebiri (okufa n’okuwona) okuteebereza omuwendo gw’abalwadde abafa.
This approach is independent of the ABC methodology and will allow comparisons between estimates from the two modelling approaches to judge robustness of results.
Enkola eno yeemalirira ku eyo eya ABC era ejja kukkiriza okugeraageranya wakati w’okuteebereza okuva mu njolekera z’okuteebereza zombi okulamula obunnyiinyiitivu bw’ebizuuliddwa.
RCGP RSC’s surveillance with PHE is defined as Health Protection under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002.
Okulondoola kwa RCGP RSC ne PHE kunnyonnyolwa nga Okwerinda mu Byobulamu mu Tteeka 3 erya Health Service (Control of Patient Information) Regulations 2002.
This has been confirmed by PHE’s Caldicott Guardian’s Office.
Kino kyakakasibwa Wofiisi ya PHE Caldicott Guardian.
We do not see any increased risk to practices or practitioners taking part in this surveillance.
Tetulaba kweyongera kwa bulabe ku bikolebwa oba abakola mu kitundu kino eky’okulondoola.
Infection prevention and control advice will follow extant national guidance.
Okuziyiza okusiigibwa obulwadde n’okutangira kujja kugoberera okuluŋŋamizibwa okw’eggwanga lyonna.
Any cases identified will be managed according to the PHE/NHS guidance in force at the time, including advice for identified contacts.
Abalwadde bonna abanaalabibwa bajja kukolebwako okusinziira ku kuluŋŋamizibwa okunaabaawo mu kiseera ekyo, omwo nga mwe muli amagezi ku bantu be banaaba bakwataganye nabo.
However, our training will include reminders about safe handling of specimens and revision of infection control measures anticipated to be high in our practices.
Wabula, okutendeka kwaffe kujja kuzingiramu okujjukiza ku nkwata ya specimen ennungi n’okwejjukanya ku kutangira okusiigibwa ebintu ebisuubira okubeera eby’amaanyi mu bye tukola.
It is a key part of Regulation 12 about safe care and treatment, periodically inspected by the Care Quality Commission.
Kitundu kikulu mu Teeka 12 erikwata ku kwegendereza n’obujjanjabi era nga lirondoolwa buli kiseera Akakiiko Akakola ku by’Omutindo (Care Quality Commission).
Travel History and Clinical Descriptors of the COVID-19 Infections
Ebyafaayo ku ntambula n’Ebinnyonnyola Obulwadde bwa COVID-19
The RCGP RSC practices have been advised on the clinical coding that has been made available for COVID-19 across all CMR systems.
Abajjanjabi ba RCGP RSC baweereddwa amagezi ku nkola y’okukozesa koodi mu ddwaliro eteereddwawo olw’obulwadde bwa COVID-19 ku miyungiro gya CMR gyonna.
This includes information on coding of clinical descriptors (Table 4) and any recent travel history.
Muno mulimu obubaka obukwata ku binnyonnyola enkozesa ya koodi (Omweso 4) n’ebikwata ku kutambula kwonna okw’emabegako.
Establishment of Extended Virology Sampling
Okumanya ebikwata ku sampolo z’okunoonyereza ku buwuka okwongezeddwayo
The RCGP RSC practices participating in the annual influenza virology surveillance have started sampling from patients showing symptoms of LRTI.
Abajjanjabi ba RCGP RSC abeetabye mu kulondoola kwa buli mwaka okw’obuwuka bwa yegu batandise okukuŋŋaanya sampolo ku balwadde abeeyolekerako obubonero bwa LRTI.
All samples received are being tested for influenza and COVID-19.
Sampolo zonna ezifunibwa zikeberebwa okulaba oba nga mulimu yegu ne COVID-19.
This has led to initial early identification of background spread in low-risk patients.
Kino kireeseewo okukenga okusookerwako mu kusaasaanya mu balwadde ab’obulabe obutono.
As of March 7, 2020, the surveillance system has detected 2 cases of COVID-19 in low-risk patients with no history of travel through extended virological sampling.
Nga 7 Ogwokusatu 2020, omuyungiro gw’okulondoola guzudde abalwadde ba COVID-19 2 mu balwadde abali mu bulabe obutono ate nga tebatambulangako era nga bafuniddwa nga bayitira mu kukuŋŋaanya sampolo z’okunoonyereza ku buwuka.
This protocol describes how we have adapted a national influenza surveillance system to monitor community spread of an unexpected infection of COVID-19.
Enseetuka eno ennyonnyola engeri gye tukozesaamu omuyungiro gw’okulondoola yegu mu nkola ey’okulondoola ensaasaana ya COVID-19 mu bitundu abantu gye babeera.
We have rapidly created and incorporated new codes to allow data recording, and are collecting data to monitor the effectiveness of containment strategies.
Ku mbiro ez’amangu tukoze era ne tuteekamu koodi empya okusobozesa okuwandiika obubaka, era tukuŋŋaanya obubaka okulondoola enkola y’obukodyo bw’okutangira nawookeera.
Through this surveillance, we intend to find out more about the epidemiology of COVID-19 in ambulatory care.
Mu kulondoola kuno, tulowooza okuzuula ebisingawo ebikwata ku nfaanana ya COVID-19 mu bujjanjabi obw’okutuuka ku bantu.
In particular, its rate of spread, both temporal and geographical.
Okusinga ennyo, embiro kwe katambulira munda mu ggwanga ate mu bitundu ebirala.
Our testing of low-risk patients will also inform whether the containment strategy that is based on virology testing of high-risk patients and their contacts plus self-isolation is effective.
Okukebera kwaffe okw’abalwadde abatalina bulabe bwa maanyi nakwo kujja kulaga oba ng’obukodyo bw’okulwanyisa nawookeera obwesigamziddwa ku kukebera omusaayi gw’abalwadde abalina obuzibu obw’amaanyi n’abo be bakwataganye nabo wamu n’omuntu okweggya mu banne bukola bulungi.
Containment should slow the spread, and there may be benefits in the management of spread from intense surveillance.
Okulwanyisa obulwadde kulina okukendeeza ku kukusaasaana kw’obulwadde era wayinza okubaawo emiganyulo mu kukola ku kusaasaana nga kuva ku kulondoola okw’amaanyi.
However, there may come a point at which the virus spreads more widely into the population, as has happened in Italy.
Wabula, wayinza okubaawo ekiseera akawuka we kasaasaanira ennyo mu bantu, nga bwe kibadde mu Italy.
Surveillance of low-risk patients should inform when we reach this tipping point and when infection rates start to remit.
Okulondooal abalwadde abali mu bulabe obutono kulina okutegeeza lwe tulina okutuuka ku ntikko eno ate n’ekiseera emiwendo gy’okukwatibwa obulwadde lwe gitandika okukka.
The epidemiology of COVID-19 remains emergent.
Ebikwata ku bulwadde bwa COVID-19 bikyasoomooza okutegeera.
The registration-based nature of UK primary care means that we will be able to create a complete picture of the cumulative incidence and duration.
Obujjanjabi bwa UK obusookerwako obwesigamiziddwa ku kwewandiisa kutegeeza tujja kusobola okusiiga ekifaananyi ekijjuvu eky’obulwadde bwonna n’ebbanga lye bumaze.
The surveillance system should be able to identify areas where COVID-19 spread is taking place that might be suitable for trials of antiviral therapy.
Omuyungo gw’okulondoola guteekwa okuba nga gusobola okukenga ebitundu COVID-19 gy’asaasaanira ebiyinza okuba ebirungi okukolerayo okugezesa eddagala erigema akawuka.
We could also follow up on the effectiveness or any adverse reactions to these medicines or vaccinations.
Tuyinza era okulondoola obukozi n’obulabe obw’engeri yonna obuleetebwa eddagala erijjanjaba oba erigema.
Finally, early detection of a confirmed COVID-19 case has exemplified the rapid implementation of this enhanced surveillance in the national network.
Ekisembayo, okuzuula amangu omulwadde wa COVID-19 kiraze obulungi bw’okussa amangu mu nkola omulimu guno ogw’okulondoola mu ggwanga lyonna.
Safety of practices is our primary concern.
Eky’okuba ng’ebikolebwa tebiriimu bulabe kye kigendererwa kyaffe ekisookerwako.
The RCGP RSC has operated for over 50 years and has been involved in collecting samples to monitor disease and vaccine effectiveness through the Hong Kong flu pandemic of 1968/69, the Russian flu of 1977/78, and the 2009 Swine flu pandemic.
RCGP RSC ebadde enkola okumala emyaka egisukka mu 50 era ebadde yeenyigira mu kukuŋŋaanya sampolo okulondoola obulungi bw’endwadde n’eddagala erigema ng’eyita mu Hong Kong flu pandemic of 1968/69, the Russian flu of 1977/78, ne 2009 Swine flu pandemic.
We are not aware of any increased risk to practice staff or other patients from involvement in surveillance.
Tetukimanyiiko nti waali wabaddewo obulabe eri abasawo oba abalwadde abalala olw’okwenyigira mu kunoonyereza.
Pandemic preparedness is part of the role of the RCGP RSC.
Okwetegekera ekizibu ky’obulwadde kye kimu ku mirimu gya RCGP RSC.
It is plausible that enhanced coding of information from contacts with the practices in RCGP RSC will reduce the likelihood of people who may be suspected COVID-19 cases being brought to the surgery inadvertently.
Kisoboka okuba nti okulamba obulungi ebikwata ku bantu abasemberera emirimu gya RCGP RSC kijja kukendeeza obusobozi bw’abantu abayinza okuteeberezebwa okuba ne COVID-19 okuleetebwa mu ddwaliro mu butanwa.
Where cases are detected unexpectedly, it is probably helpful for that patient, their contacts, and the practice to know.
Mu mbeera ng’abalwadde bazuuliddwa mu ngeri ebadde tesuubirwa, kya mugaso eri omulwadde oyo, abo abamusemberedde, n’abasawo okumanya.
The impact on practices has been to close for a day, if a case is found, for deep cleaning and then reopen.
Ekibaddenga kikolebwa kwe kuggalawo okumala olunaku, nga waliwo omulwadde azuuliddwa, olw’okulongoosa okw’amaanyi ate ne baggulawo oluvannyuma.
The principal limitations of our system are the number of data points.
Obuzibu obusinga obunene mu nkola yaffe gwe muwendo gw’ebifo by’obubaka ebingi.
We are collecting serology and virology data from 100 sites, which covers a small group of the population.
Tukuŋŋaanya obubaka bw’amazzi g’omubiri n’obuwuka (serology and virology data) okuva mu bifo 100, nga bino bikwata ku kibinja kitono ku bantu be tulina okunoonyerezaako.
This has been satisfactory for monitoring influenza, but we are not certain if this is a sufficiently large sample for the COVID-19 outbreak.
Kino kibadde kimatiza mu kulondoola ssenyiga, naye tetukakasa oba ng’omuwendo gwa sampolo guno munene ekimala ku kizibu kya COVID-19.
Our sites (surveillance practices) are currently fixed, and it could be helpful to be able to rapidly onboard practices in regions where there are more cases.
Ebifo byaffe (surveillance practices) mu kiseera kino bigere, era nga kyandibadde kiyamba okusobola okugattako mu bwangu emirimu egikolebwa mu bitundu ewali abalwadde abangi.
Currently, we will be reporting weekly.
Mu kiseera kino, tujja kuba tufulumya alipoota buli wiiki.